Cymabay Therapeutics, Inc. (NASDAQ:CBAY) slipped over -0.56% at $8.89, after hitting low of $8.76 in an intra-day trade. Cymabay Therapeutics, Inc. has 41.81 million shares outstanding, and in the last trade has seen ATR around 0.49. The volume of CBAY witnessed a shift from 904.46 thousand shares, based on a 50-day average, to 1.26 million shares.

In the most updated research from a number of analysts on Wall Street, the company gets 7 Buys and 0 Sell among 7 analysts. Cymabay Therapeutics, Inc. (NASDAQ:CBAY) recently traded as high as $9.2. The consensus analyst target price is $13.57. That gives us a street projected return of 52.64%. If the published price targets set by Cymabay Therapeutics, Inc. analysts have any power to influence the stock’s share price, the highest price target set for CBAY is $16.

On a similar note, analysts expect EPS of -$0.19 in September 2017 quarter and -$0.14 in December 2017 quarter, representing -24% and -53.33% growth, respectively. They expect this year’s earnings to fall -28.07% year-over-year to -$0.82, followed by -9.76% decline in the next year to -$0.74.

Shares of Hanesbrands Inc. (NYSE:HBI) traded down -0.55% in the last session while performance was up 23.66% in the last five days. The stock’s last price was lower from the average trading price of 50 days recorded at $24.36 while enlarging the period to 200 trading days, the average price was $22.31. Currently, 363.71 million total shares are owned by the public and among those 360.87 million shares have been available to trade. The percentage of shares being held by the company management was 0.5% while institutional stake was 97.1%.

Hanesbrands Inc. (HBI) is recuperating from the fall at $18.91, the 52-week low. The stock has risen 25.12% since then. The trading saw a strength at $27.07 , the 52-week high. But since then, those gains have faded by -12.6%. HBI has lost -7.58% in the 1-month period.

Cymabay Therapeutics, Inc. has a beta of 0.77, offering the possibility of a higher rate of return, but also posing more risk. The portion of a company’s profit allocated to each outstanding share of common stock was $1.52 a share in the trailing twelve months. It last reported revenues of $1.65 billion and EPS of $0.53 for the June 2017, representing 12% top-line growth and 0.51 EPS growth.

Looking forward, the company’s quarterly earnings are expected to come at $0.6 in the three months through September 2017 and $0.57 in the quarter ending December 2017, reflecting 7.14% and 7.55% growth, respectively. For the full year, analysts expect earnings to jump 7.03% yoy to $1.98. Next year this growth will reach 8.08% to attain $2.14.